BREAST CANCER

NEOADJUVANT THERAPY

HR-positive HER2-negative

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

IRB# 21243
Neoadjuvant Abemaciclib and Niraparib (PANNTHR)

HER2-positive

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

Triple Negative

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

http://www.ohsu.edu/research/rda/soc/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold
HR-positive
HER2-negative

IRB#22395
DARE: DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III

HER2-positive
No trials currently available

Triple Negative
No trials currently available

http://www.ohsu.edu/research/rda/so/knight.php
BREAST CANCER

METASTATIC THERAPY

HR-positive HER2-negative

ENDOCRINE

Physician's Choice

CHEMO

1L

IRB#22730
SERENA-4: AZD9833 with palbociclib vs. anastrozole with palbociclib

2L

IRB#22225
OP-1250-001: A Dose Escalation/Expansion study of OP-1250

IRB#21441
EA1183: FDG-PET/CT

IRB#23425
Keynote-B49: Pembrolizumab/Placebo Plus Chemotherapy

IRB#23524
TROPION-Breast01: DATO-DXd vs. Chemo

>2L

IRB#22225
OP-1250-001: A Dose Escalation/Expansion study of OP-1250

IRB#21441
EA1183: FDG-PET/CT

IRB#23524
TROPION-Breast01: DATO-DXd vs. Chemo

http://www.ohsu.edu/research/rda/soc/knight.php

11 Oct 2022
METASTATIC THERAPY

HER2-positive

1L

IRB#21441
EA1183: FDG-PET/CT

2L

IRB#21441
EA1183: FDG-PET/CT

>2L

http://www.ohsu.edu/research/rda/so/knight.php
BREAST CANCER

METASTATIC THERAPY

Triple Negative

1L

IRB#18504
AMTEC: Olaparib + Durvalumab

>2L

IRB#18504
AMTEC: Olaparib + Durvalumab

IRB#18504
AMTEC: Olaparib + Durvalumab

IRB#22229: Early Phase 1 study of WEE1 inhibitor, ZN-c3

http://www.rda/}

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold
<table>
<thead>
<tr>
<th>Trial ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB#15588</td>
<td>• Heavily Pre-treated • HR+HER2--; HER2+; TNBC</td>
</tr>
<tr>
<td>IRB#20679</td>
<td>• HR+HER2--; HER2+; TNBC • Pre-screen (molecular target)</td>
</tr>
<tr>
<td>IRB#19904</td>
<td>• Heavily Pre-treated • Pre-screen required</td>
</tr>
<tr>
<td>IRB#19992</td>
<td>• Pre-screen (molecular target)</td>
</tr>
<tr>
<td>IRB#18084</td>
<td>• Pre-screen (rare molecular target)</td>
</tr>
<tr>
<td>IRB#19489</td>
<td>• Targeting Metastatic Breast Cancer and Breast Cancer Stem Cells with Lutathera</td>
</tr>
<tr>
<td>IRB#18164</td>
<td>• RET fusion-positive</td>
</tr>
</tbody>
</table>

http://www.ohsu.edu/research/rda/so/knight.php
<table>
<thead>
<tr>
<th>IRB#</th>
<th>Trial Name</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB#21349</td>
<td>MML1 (Phase 1)</td>
<td>• TNBC stage IV or locally advanced and unresectable. Progressed after at least 1 line or for whom no standard therapy has failed, or for whom standard therapy has failed, or for whom standard therapy is contraindicated.</td>
</tr>
<tr>
<td>IRB# 22902</td>
<td>Firelight (Phase 1)</td>
<td>• All solid tumors with MAPK pathway alteration</td>
</tr>
<tr>
<td>IRB#22580</td>
<td>ELVCAP (Phase 1)</td>
<td>• Metastatic solid tumor with an NRG1 gene fusion.</td>
</tr>
<tr>
<td>IRB#21819</td>
<td>ASTX029 (Phase 1)</td>
<td>• Phase 1B: documented activating gene mutations in BRAF (BRAF V600 mutation or activating atypical non-V600 aberrations), KRAS, NRAS, or HRAS</td>
</tr>
<tr>
<td>IRB #21998</td>
<td>PMV (Phase 1)</td>
<td>• Patient has a histologically or cytologically confirmed advanced solid malignancy with a p53 Y220C mutation.</td>
</tr>
<tr>
<td>IRB# 22223</td>
<td>PY159 (Phase 1)</td>
<td>• TNBC and Breast HR+/HER2- with locally advanced or metastatic disease that has relapsed or refractory to at least one line of post-adjuvant therapy.</td>
</tr>
</tbody>
</table>

To inquire about Phase 1 trial open slots please contact Phase1@ohsu.edu.

http://www.ohsu.edu/research/rda/sc/knight.php
• TNBC that has progressed through at least 1 line of therapy for metastatic or locally advanced disease

• TNBC and HR+ HER2- locally advanced or metastatic that has relapsed or refractory to at least one line of post-adjuvant and not eligible for other targeted therapies.

• Part A (dose escalation) metastatic or locally advanced solid tumors

• A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors. Principal Investigator: Richard Maziarz, MD

A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid-Tumor Malignancies. Yazan Migdady, MD

http://www.ohsu.edu/research/rda/so/knight.php